Population pharmacokinetics of telavancin in healthy subjects and patients with infections.
about
Telavancin in the treatment of Staphylococcus aureus hospital-acquired and ventilator-associated pneumonia: clinical evidence and experience.Telavancin pharmacokinetics and pharmacodynamics in patients with complicated skin and skin structure infections and various degrees of renal function.In Vitro Pharmacodynamics of Human Simulated Exposures of Telavancin against Methicillin-Susceptible and -Resistant Staphylococcus aureus with and without Prior Vancomycin Exposure.Evaluation of Pharmacodynamic Interactions Between Telavancin and Aztreonam or Piperacillin/Tazobactam Against Pseudomonas aeruginosa, Escherichia coli and Methicillin-Resistant Staphylococcus aureus.Telavancin: a review of its use in patients with nosocomial pneumonia.Telavancin (VIBATIV) for the treatment of complicated skin and skin structure infections.Telavancin: the long and winding road from discovery to food and drug administration approvals and future directions.Pharmacodynamics, pharmacokinetics and clinical efficacy of telavancin in the treatment of pneumonia.Dosing strategies to optimize currently available anti-MRSA treatment options (Part 1: IV options).Comprehensive Guidance for Antibiotic Dosing in Obese Adults.Pharmacokinetics of hydroxymethylnitrofurazone, a promising new prodrug for Chagas' disease treatmentIntegration of biostatistics and pharmacometrics computing platforms for efficient and reproducible PK/PD analysis: a case study.Pharmacokinetics of Telavancin at Fixed Doses in Normal Body Weight and Obese (Classes I, II, and III) Adult Subjects.
P2860
Q34677611-A3497134-3611-460B-82FC-FF769D4F5D32Q35867360-5947AE9D-3C6F-490D-B5C0-7307FB8D5561Q36439072-FA3961B8-EE7B-4768-ABA5-34B2C57CAF6BQ37250189-39587C21-4EE8-4B08-A8F4-D9AA2A4669D9Q38159966-9E9BEA1F-AF67-4832-95F3-9D126EC2E02CQ38522574-A9BA11B9-D066-4C96-A522-CC190AF55A1FQ38575714-CD7CD7BE-14CE-405F-99E1-88DDCDA7B9B0Q38829519-7921A4DC-24C6-497A-8377-87F8E0ACBB7FQ38907793-7990BD74-109A-4480-A769-C43DC40A5A91Q40067964-D6C2D465-6E4D-4C5A-A068-FC22A2959913Q42098034-DBAB19FC-A709-46D0-8CFA-C96C3800D7FEQ44777428-90EF2E6A-67D4-469A-AEE4-8EDEDA599D28Q47172132-1AE8CC52-E4A9-4060-93FA-BA010BDDD144
P2860
Population pharmacokinetics of telavancin in healthy subjects and patients with infections.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Population pharmacokinetics of ...... and patients with infections.
@ast
Population pharmacokinetics of ...... and patients with infections.
@en
type
label
Population pharmacokinetics of ...... and patients with infections.
@ast
Population pharmacokinetics of ...... and patients with infections.
@en
prefLabel
Population pharmacokinetics of ...... and patients with infections.
@ast
Population pharmacokinetics of ...... and patients with infections.
@en
P2093
P2860
P356
P1476
Population pharmacokinetics of ...... and patients with infections.
@en
P2093
Emil Samara
Jeng-Pyng Shaw
Philip Worboys
Shekman L Wong
Steven L Barriere
P2860
P304
P356
10.1128/AAC.05915-11
P407
P577
2012-01-17T00:00:00Z